Alnylam Pharmaceuticals has seen a strong start to
2025 backed by robust Q1 financial performance- beating earnings estimates and marking high-revenue growth.
AMVUTTRA® (vutrisiran), as the first RNAi therapeutic to reduce cardiovascular death and heart related complications in adult patients with ATTR amyloidosis and cardiomyopathy, was approved by the FDA. In addition, it received CHMP (Committee for Medicinal Products for Human Use) backing in Europe. Analysts foresee limited tariff risk and the momentum of Amvuttra. UBS, issued a positive stance, adjusting price target and maintaining a buy rating. The price target was consequently raised by others including Ch. The company's diversified pipeline is making progress, while its strategic positioning and growth prospects is appreciated.
Novartis's acquisition of Regulus could spread impact on the kidney disease drug market. A 20-year investment review shows substantial value growth. Alnylam announced the retirement of Dr. Phillip A. Sharp, a key co-founder and industry luminary, from board membership. The company submitted a supplemental new drug application (sNDA) to the FDA for vutrisiran.
Alnylam Pharmaceuticals News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Fri, 02 May 2025 23:30:22 GMT -
Rating 7
- Innovation 9
- Information 8
- Rumor -5
